Senior Management

Mark Parry-Billings, PhD

Managing Director
Dr. Parry-Billings was appointed in 2017 and he also holds the position of Head of Corporate Drug Development for the Chiesi Group. Previously he held leadership positions in R&D for Companies in the UK and Canada. Dr. Parry-Billings holds a PhD in Biochemistry from University of Oxford.

Team Management

Claes Andersson, PhD

Research Director
Stockholm, Sweden
Dr. Andersson joined Zymenex in 1999 as Manager of Biochemistry and was appointed Research Director in 2006. Prior to joining Zymenex, Dr. Andersson has held positions as Scientist, Project Manager and group- and section Manager at Pharmacia & Upjohn, Sweden.
Dr. Andersson holds a PhD degree in Biochemistry from Stockholm University and Karolinska Institute, Sweden and is the author of several patents and publications within the field of biochemistry and biotechnology.

Nina Herne, PhD, MBA

Head of Development
Stockholm, Sweden
Dr. Herne joined Zymenex in September 2017 as responsible for development of projects within enzyme replacement therapies and advanced therapies.
Prior to joining Zymenex, Dr. Herne held several senior positions including Head of CMC, Alliance Manager and Global Senior Program Director at companies such as NeuroNova and Swedish Orphan Biovitrum (Sobi).
Dr. Herne holds a PhD in Immunology from Lund University and a MBA from Stockholm School of Economics.


Board of Directors

Jens Fogh, Chairman
Mark Parry-Billings, Managing Director
Claes Andersson, Research Director

Zymenex A/S Roskildevej 12 C
3400 Hillerød, DK
Tel  +45 48250054
Fax  +45 48251054
Affiliate Sweden Agavägen 58
181 55 Lidingö, S
Tel  +46 8 7670203
Fax  +46 8 7670233

© 2004 Zymenex A/S